These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 28982487)

  • 1. Management of Muscle-Invasive Urothelial Cancer and the Emerging Role of Immunotherapy in Advanced Urothelial Cancer.
    Giridhar KV; Kohli M
    Mayo Clin Proc; 2017 Oct; 92(10):1564-1582. PubMed ID: 28982487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Changing Treatment Landscape for Metastatic Urothelial Carcinoma.
    Flaig TW
    J Natl Compr Canc Netw; 2018 May; 16(5S):636-638. PubMed ID: 29784744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sentinel node detection in muscle-invasive urothelial bladder cancer is feasible after neoadjuvant chemotherapy in all pT stages, a prospective multicenter report.
    Rosenblatt R; Johansson M; Alamdari F; Sidiki A; Holmström B; Hansson J; Vasko J; Marits P; Gabrielsson S; Riklund K; Winqvist O; Sherif A
    World J Urol; 2017 Jun; 35(6):921-927. PubMed ID: 27738804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent developments in the treatment of advanced bladder cancer.
    Godwin JL; Hoffman-Censits J; Plimack E
    Urol Oncol; 2018 Mar; 36(3):109-114. PubMed ID: 29395952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autophagy and urothelial carcinoma of the bladder: A review.
    Chandrasekar T; Evans CP
    Investig Clin Urol; 2016 Jun; 57 Suppl 1(Suppl 1):S89-97. PubMed ID: 27326411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel therapeutic targets in advanced urothelial carcinoma.
    Rouanne M; Loriot Y; Lebret T; Soria JC
    Crit Rev Oncol Hematol; 2016 Feb; 98():106-15. PubMed ID: 26589398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma.
    Teo MY; Rosenberg JE
    Urol Clin North Am; 2018 May; 45(2):287-295. PubMed ID: 29650143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bladder cancer.
    Gwynn ES; Clark PE
    Curr Opin Oncol; 2006 May; 18(3):277-83. PubMed ID: 16552241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individualized management of advanced bladder cancer: Where do we stand?
    Burgess EF
    Urol Oncol; 2015 Apr; 33(4):187-95. PubMed ID: 24332641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New concepts in the management of MIBC in 2010].
    Pignot G; Molinié V; Coloby P; Culine S; Gravis G; Rossi D; Theodore C; Zerbib M
    Prog Urol; 2011 Mar; 21 Suppl 2():S38-42. PubMed ID: 21397826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chemotherapy for urothelial cancer of the bladder--update 2012].
    Niegisch G; Lorch A; Albers P
    Aktuelle Urol; 2012 Dec; 43(6):412-9. PubMed ID: 23196781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecularly-driven precision medicine for advanced bladder cancer.
    Krabbe LM; Margulis V; Schrader AJ; Shariat SF; Gust KM; Boegemann M
    World J Urol; 2018 Nov; 36(11):1749-1757. PubMed ID: 29948043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Neoadjuvant or Adjuvant Chemotherapy for Bladder Cancer?].
    Hupe MC; Kramer MW; Kuczyk MA; Merseburger AS
    Aktuelle Urol; 2015 May; 46(3):242-7. PubMed ID: 26077309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant Therapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma.
    Achkar T; Parikh RA
    Urol Clin North Am; 2018 May; 45(2):257-266. PubMed ID: 29650141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perioperative chemotherapy in advanced bladder cancer: part I. Neoadjuvant treatment.
    Goebell PJ; Otto T; Rübben H
    Onkologie; 2003 Aug; 26(4):361-5. PubMed ID: 12972704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular and histopathology directed therapy for advanced bladder cancer.
    Alifrangis C; McGovern U; Freeman A; Powles T; Linch M
    Nat Rev Urol; 2019 Aug; 16(8):465-483. PubMed ID: 31289379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urothelial cancers: using biology to improve outcomes.
    Pezaro C; Liew MS; Davis ID
    Expert Rev Anticancer Ther; 2012 Jan; 12(1):87-98. PubMed ID: 22149435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developing innovative strategies for advanced transitional cell carcinoma of the bladder.
    Pollera CF; Nelli F
    Expert Rev Anticancer Ther; 2006 Jan; 6(1):83-92. PubMed ID: 16375647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors.
    Mollica V; Maggio I; Lopez-Beltran A; Montironi R; Cimadamore A; Cheng L; Rizzo A; Giunchi F; Schiavina R; Fiorentino M; Brunocilla E; Massari F
    Expert Rev Anticancer Ther; 2020 Sep; 20(9):755-763. PubMed ID: 32757789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder.
    Kluth LA; Xylinas E; Crivelli JJ; Passoni N; Comploj E; Pycha A; Chrystal J; Sun M; Karakiewicz PI; Gontero P; Lotan Y; Chun FK; Fisch M; Scherr DS; Shariat SF
    J Urol; 2013 Aug; 190(2):480-6. PubMed ID: 23376707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.